JP2023018678A5 - - Google Patents

Download PDF

Info

Publication number
JP2023018678A5
JP2023018678A5 JP2022119632A JP2022119632A JP2023018678A5 JP 2023018678 A5 JP2023018678 A5 JP 2023018678A5 JP 2022119632 A JP2022119632 A JP 2022119632A JP 2022119632 A JP2022119632 A JP 2022119632A JP 2023018678 A5 JP2023018678 A5 JP 2023018678A5
Authority
JP
Japan
Prior art keywords
seq
cdr
amino acid
acid sequence
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022119632A
Other languages
English (en)
Japanese (ja)
Other versions
JP7638935B2 (ja
JP2023018678A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2023018678A publication Critical patent/JP2023018678A/ja
Publication of JP2023018678A5 publication Critical patent/JP2023018678A5/ja
Priority to JP2025023976A priority Critical patent/JP2025081477A/ja
Application granted granted Critical
Publication of JP7638935B2 publication Critical patent/JP7638935B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022119632A 2021-07-27 2022-07-27 抗ccr8抗体 Active JP7638935B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025023976A JP2025081477A (ja) 2021-07-27 2025-02-18 抗ccr8抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163226118P 2021-07-27 2021-07-27
US63/226,118 2021-07-27

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025023976A Division JP2025081477A (ja) 2021-07-27 2025-02-18 抗ccr8抗体

Publications (3)

Publication Number Publication Date
JP2023018678A JP2023018678A (ja) 2023-02-08
JP2023018678A5 true JP2023018678A5 (cg-RX-API-DMAC7.html) 2024-09-09
JP7638935B2 JP7638935B2 (ja) 2025-03-04

Family

ID=82898810

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022119632A Active JP7638935B2 (ja) 2021-07-27 2022-07-27 抗ccr8抗体
JP2025023976A Pending JP2025081477A (ja) 2021-07-27 2025-02-18 抗ccr8抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025023976A Pending JP2025081477A (ja) 2021-07-27 2025-02-18 抗ccr8抗体

Country Status (27)

Country Link
US (1) US11639393B2 (cg-RX-API-DMAC7.html)
EP (2) EP4491635A3 (cg-RX-API-DMAC7.html)
JP (2) JP7638935B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250135339A (cg-RX-API-DMAC7.html)
CN (1) CN117425677A (cg-RX-API-DMAC7.html)
AR (1) AR126578A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022317803A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024837A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220121A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015915A2 (cg-RX-API-DMAC7.html)
DK (1) DK4214240T3 (cg-RX-API-DMAC7.html)
ES (1) ES2995868T3 (cg-RX-API-DMAC7.html)
FI (1) FI4214240T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241561T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069018T2 (cg-RX-API-DMAC7.html)
IL (2) IL319478A (cg-RX-API-DMAC7.html)
LT (1) LT4214240T (cg-RX-API-DMAC7.html)
MX (1) MX2023014154A (cg-RX-API-DMAC7.html)
PL (1) PL4214240T3 (cg-RX-API-DMAC7.html)
PT (1) PT4214240T (cg-RX-API-DMAC7.html)
RS (1) RS66234B1 (cg-RX-API-DMAC7.html)
SA (1) SA523451582B1 (cg-RX-API-DMAC7.html)
SI (1) SI4214240T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400483T1 (cg-RX-API-DMAC7.html)
TW (2) TWI920354B (cg-RX-API-DMAC7.html)
WO (1) WO2023010054A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309516B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
CN120076829A (zh) 2022-10-18 2025-05-30 明治制果药业株式会社 T细胞肿瘤的治疗剂
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
WO2024248037A1 (ja) 2023-05-30 2024-12-05 塩野義製薬株式会社 Ccr8を抗原として認識する二重特異性抗体
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CN109715653A (zh) 2016-05-16 2019-05-03 驰科迈博有限责任公司 肿瘤浸润调节性t细胞中被选择性地去调节的标志物
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
PT3431105T (pt) 2017-03-29 2020-03-11 Shionogi & Co Composição medicinal para tratamento de cancro
BR112021011431A2 (pt) * 2018-12-27 2021-11-23 Univ Osaka Anticorpo monoclonal ou um fragmento de anticorpo do mesmo que se liga ao ccr8, seu uso, bem como composição farmacêutica, polinucleotídeo, vetor de expressão e kit
AU2021205877B2 (en) 2020-01-06 2024-06-20 Vaccinex, Inc. Anti-CCR8 antibodies and uses thereof
TWI890283B (zh) * 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US20250019449A1 (en) 2020-03-05 2025-01-16 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
AU2021244200A1 (en) 2020-03-23 2022-11-24 Bristol-Myers Squibb Company Anti-CCR8 antibodies for treating cancer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
JP7610302B2 (ja) 2020-08-28 2025-01-08 ハーバー・バイオメド・(シャンハイ)・カンパニー・リミテッド Ccr8抗体及びその用途
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
AU2021277712B2 (en) 2020-10-16 2023-05-25 LaNova Medicines Limited Anti-CCR8 monoclonal antibodies and uses thereof
WO2022136649A1 (en) 2020-12-24 2022-06-30 Oncurious Nv Non-blocking human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders

Similar Documents

Publication Publication Date Title
JP2024167313A5 (cg-RX-API-DMAC7.html)
JP2025081477A5 (cg-RX-API-DMAC7.html)
JP2022177090A5 (cg-RX-API-DMAC7.html)
JP2018108081A5 (cg-RX-API-DMAC7.html)
JP2022061992A5 (cg-RX-API-DMAC7.html)
JP2009225799A5 (cg-RX-API-DMAC7.html)
JP2020524000A5 (cg-RX-API-DMAC7.html)
JP2023081303A5 (cg-RX-API-DMAC7.html)
JP2024086870A5 (cg-RX-API-DMAC7.html)
JP2025032102A5 (cg-RX-API-DMAC7.html)
HRP20190932T1 (hr) Molekule protutijela koje se vežu na il-17a i il-17f
JP2023545183A5 (cg-RX-API-DMAC7.html)
FI4214240T3 (fi) Ccr8-vasta-aineita
JP2022523442A5 (cg-RX-API-DMAC7.html)
JP2017052784A5 (cg-RX-API-DMAC7.html)
RU2016119152A (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2024109911A5 (cg-RX-API-DMAC7.html)
CN115461368A (zh) 抗人白细胞介素-4受体α抗体及其制备方法和应用
JP2020037555A5 (cg-RX-API-DMAC7.html)
JP2012525829A5 (cg-RX-API-DMAC7.html)
RU2011110169A (ru) Антитела против ccr2
JP2009539348A5 (cg-RX-API-DMAC7.html)
JP2023093753A5 (cg-RX-API-DMAC7.html)
JP2024105229A5 (cg-RX-API-DMAC7.html)
JP2013544078A5 (cg-RX-API-DMAC7.html)